- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.06. | LakeShore Biopharma Co., Ltd. - 15-12G, Securities registration termination | 5 | SEC Filings | ||
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 24.06. | EQS-News: LAKESHORE BIOPHARMA CO., LTD: LakeShore Biopharma Announces Completion of Going Private Transaction | 404 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma Announces Completion of Going Private Transaction 24.06.2026 / 18:13 CET/CEST
The issuer... ► Artikel lesen | |
| 22.06. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 19.06. | EQS-News: LakeShore Biopharma Co., Ltd: LakeShore Biopharma Announces Shareholders' Approval of Merger Agreement | 476 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma Announces Shareholders' Approval of Merger Agreement 19.06.2026 / 14:05 CET/CEST
The issuer... ► Artikel lesen | |
| 28.05. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.05. | EQS-News: LakeShore Biopharma Co., Ltd: LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders | 476 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders 28.05.2026 / 15:15 CET/CEST
The issuer... ► Artikel lesen | |
| 29.04. | EQS-News: LakeShore Biopharma Co., Ltd: LakeShore Biopharma Enters Into Amended Merger Agreement for Going-Private Transaction | 468 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma Enters Into Amended Merger Agreement for Going-Private Transaction 29.04.2026 / 14:03 CET/CEST
The... ► Artikel lesen | |
| 29.04. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.03. | LakeShore Biopharma receives reduced buyout offer at $0.06/share | 1 | Investing.com | ||
| 25.03. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.02. | LakeShore Biopharma's $0.90 per share going-private deal at risk | 1 | Investing.com | ||
| 06.02. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.09.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.09.2025 | 1.372 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 30.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.09.2025ISIN NameCA8875221001 TINKA... ► Artikel lesen | |
| 22.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting | 380 | PR Newswire | BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 12.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq | 995 | PR Newswire | BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 28.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee | 636 | PR Newswire | BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 18.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company | 324 | PR Newswire | BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,720 | -0,75 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,09 | -0,08 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| PRAXIS PRECISION MEDICINES | 307,53 | -0,07 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | ||
| MONTE ROSA THERAPEUTICS | 16,565 | -26,96 % | Warum die Aktie von Monte Rosa Therapeutics heute abstürzt | ||
| COGENT BIOSCIENCES | 39,180 | -5,27 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,150 | -2,16 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| TRAVERE THERAPEUTICS | 56,11 | +0,99 % | Everest Medicines Limited: Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,130 | -2,33 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 74,78 | -4,37 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| BIONTECH | 79,05 | -1,37 % | Chancen & Risiken bei den Q.2-Kennzahlen - Almonty Industries, BioNTech, Danaher, Pfizer, Sartorius | Die globalen Aktienmärkte bleiben dynamisch, und die fundamentalen Rahmenbedingungen haben sich in den letzten Quartalen rasant verändert. Im heutigen Bericht analysieren wir drei faszinierende Unternehmen... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 20,380 | +3,29 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| ERASCA | 18,140 | +2,37 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 103,90 | -1,29 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| VERA THERAPEUTICS | 32,120 | -2,81 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,880 | -3,97 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen |
Das Unternehmen LAKESHORE BIOPHARMA CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,665 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.